James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Why Tesla Motors (TSLA), Cooper Tire & Rubber (CTB) and Sprint (S) Are 3 of Today’s Worst Stocks

Sprint Corp., Tesla Motors Inc. and Cooper Tire & Rubber Co. couldn't win for losing on Monday. Here's what happened.

VRX: What Valeant Pharmaceuticals is Really Getting With Salix

Valeant Pharmaceuticals is bringing Salix Pharmaceuticals into the fold for its portfolio and pipeline, but was it really worth the hefty price?

Why Brocade Communications Systems, Inc. Iron Mountain Inc. and Discovery Communications Inc. Are 3 of Today’s Worst Stocks

Brocade Communications Systems, Iron Mountain and Discovery Communications just couldn't win for losing today. Here's the deal.

4 Gold Stocks to Buy on a Dip

Yamana Gold, AngloGold Ashanti, Goldcorp and Barrick Gold have quietly become your best gold stocks in the midst of a choppy environment.

Vivus, Inc. (VVUS): Earnings Preview

The VIVUS earnings report coming on Monday could be a harsh reality check about the long-term prospects for Qsymia.